This is a revolutionary development for cardiac disease (and probably stroke too!)

“A single dose of Eli Lilly & Co.’s experimental drug cut a risk factor that signals heart disease by 94% for almost a year, a first-in-human study found. 

Lilly’s lepodisiran, given at the highest dose, reduced a heart disease-linked protein to undetectable levels for 48 weeks. The research raises hopes that an annual vaccine-like shot could eliminate lipoprotein (a) in people whose genes put them at high risk, said Steve Nissen, a cardiologist at the Cleveland Clinic in Ohio who led the study.”